Annexon, Inc. (ANNX) vs Starling Oncology, Inc. (STLN)

A side-by-side comparison of Annexon, Inc. and Starling Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Annexon, Inc. logo
ANNX
Annexon, Inc.
$667M
$4.07HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT
Starling Oncology, Inc. logo
STLN
Starling Oncology, Inc.
$655M
$6.55HealthcareDelayed quote: Oct 6, 2026, 2:40 PM EDT

Total return — ANNX vs STLN

growth of $100 · dividends reinvested · last 1y
ANNX -29.5% (-29.5%/yr)STLN +8.6% (+8.6%/yr)STLN compounded faster over this window
6080100120Start $100$70$109
ANNX STLN

ANNX vs STLN: by the numbers

  • •ANNX is the larger company ($667M vs $655M market cap).
  • •Both run net losses; ANNX's is the smaller (0.00% vs -6.18% net margin).

Metrics side by side

Valuation

MetricANNXSTLN
P/S ratioN/A1.12
P/B ratio3.59N/A

Profitability

MetricANNXSTLN
Gross margin0.00%15.69%
Operating margin0.00%-4.44%
Net margin0.00%-6.18%
ROE-108.93%N/A
ROIC-101.43%-31.32%

Growth (annualized)

MetricANNXSTLN
Total return CAGR (5Y)-26.29%N/A

Go deeper

Full ANNX analysisFull STLN analysisInteractive comparison tool

Dig into the metrics

Annexon ROEStarling Oncology ROEAnnexon operating marginStarling Oncology operating marginAnnexon revenue growthStarling Oncology revenue growthAnnexon free cash flowStarling Oncology free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.